Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX26 + serplulimab in previously treated metastatic colorectal cancer
CTR20222602Phase 2Terminated
- Sponsor
- Henlius
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of hlx26, serplulimab in metastatic colon cancer (mCRC), sponsored by Henlius. Started Oct 2022; status: terminated.
02
Drugs
hlx26serplulimab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20222602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222602.